Mutagenic Evaluation of Fluoxetine and Fluoxetine-Galactomannan Complex Through the Analysis of Chromosomal Aberrations in Human Peripheral Leukocytes and Salmonella typhimurium/Microssome Assay

Bruno Coêlho Cavalcanti; Cecília Rocha da Silva; João Batista de Andrade Neto; Maria Aparecida Alexandre Josino; Lívia Gurgel do Amaral Valente Sá; Antônio Adailson de Sousa Silva; Francisco Stefânio Barreto; José Roberto de Oliveira Ferreira; Hemerson Iury Ferreira Magalhães; Ícaro Gusmão Pinto Vieira; Débora Hellen Almeida Brito; Nágila Maria Pontes Silva Ricardo; Fátima Daiana Dias Barroso; Érica Rayanne Mota da Costa; Hélio Vitoriano Nobre Júnior; Manoel Odorico de Moraes

doi:10.12662/2317-3076jhbs.v10i1.4461.p1-6.2022

Mutagenic Evaluation of Fluoxetine and Fluoxetine-Galactomannan Complex Through the Analysis of Chromosomal Aberrations in Human Peripheral Leukocytes and Salmonella typhimurium/Microssome Assay

Bruno Coêlho Cavalcanti, Cecília Rocha da Silva, João Batista de Andrade Neto, Maria Aparecida Alexandre Josino, Lívia Gurgel do Amaral Valente Sá, Antônio Adailson de Sousa Silva, Francisco Stefânio Barreto, José Roberto de Oliveira Ferreira, Hemerson Iury Ferreira Magalhães, Ícaro Gusmão Pinto Vieira, Débora Hellen Almeida Brito, Nágila Maria Pontes Silva Ricardo, Fátima Daiana Dias Barroso, Érica Rayanne Mota da Costa, Hélio Vitoriano Nobre Júnior, Manoel Odorico de Moraes

Resumo

Objectives: The purpose of this study was to evaluate the mutagenic potential of fluoxetine and fluoxetine-galactomannan. Methods: Chromosomal aberration test and Salmonella typhimurium/microsome mutagenicity assay. Results: The results showed that fluoxetine (250 μg/mL) can cause chromosomal breaks of treated leukocytes and increase the frequency of reversion of the tester strains of S. typhimurium / microsome assay only at the highest concentration (5 mg/mL), while fluoxetine encapsulated in galactomannan did not cause these changes (leukocytes and S. typhimuriums strains). Conclusion: In summary, fluoxetine showed a mutagenic effect detectable only at high concentrations in both eukaryotic and prokaryotic models. Furthermore, the fluoxetine/galactomannan complex, in this first moment, prevented the mutagenicity attributed to fluoxetine, emphasizing that the present encapsulation process can be an alternative in preventing these effects in vitro.